drugset / Trial / NCT02057796

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

NCT02057796

Phase 4 Completed 1050 enrolled ANRS, Emerging Infectious Diseases
RandomizedParallel-groupOpen-labelPrevention

Summary

In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections are leading causes of early death in patients who initiate antiretroviral therapy (ART) with advanced immunodeficiency. We hypothesize that a systematic 6-month empirical TB treatment initiated 2 weeks before the introduction of ART in HIV-infected adults with severe immunosuppression (CD4\<100/mm3) and no overt evidence of TB will reduce the risk of death and invasive bacterial infections. This strategy will be compared to one of extensive TB testing using point-of-care tests (Xpert MTB/RIF® and urine lipoarabinomanan LAM) and chest X-ray to identify and treat only patients with at least one positive test suggestive of TB.

Timeline

Start
2014-09
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethambutol Small molecule
Subject Isoniazid Small molecule
Subject Pyrazinamide Small molecule
Subject Rifampin Small molecule
Background Atripla Unknown
Background Efavirenz Other / unclassified
Background Lamivudine Other / unclassified
Background Tenofovir Small molecule